We transform the most promising oncology innovations into highly competitive opportunities that benefit patients, researchers, investors, and Ontario's economy. Cancer Breakthroughs. Realized.

FACIT Announces Six Finalists for 2019 Falcons' Fortunes Pitch Competition

The pitch competition showcases six Ontario-based entrepreneurial researchers working in the oncology space to pitch their innovative research ideas to a panel of judges.

The 6th annual Falcons’ Fortunes competition will be held in Toronto on Thursday, April 4, 2019. 

FACIT Features: Portfolio company Fusion Pharma launches Phase 1 trial for next-gen radiotherapeutic

FACIT congratulates portfolio company Fusion Pharma on significant clinical development milestone.

Fusion Pharma announced the first patient dosing with lead candidate in Phase 1 trial for solid tumors.

FACIT in the News - @globeandmail

"For innovation, open science means open for business", February 6, 2019

https://www.theglobeandmail.com/business/ commentary/article-for-innovation-open-science-means-open-for-business/

FACIT in the News - @globeandmail

"U.S. biotech giant Celgene invests in Ontario-developed blood-cancer drug in potential $1-billion deal", January 29, 2019

https://www.theglobeandmail.com/business/ article-us-biotech-giant-celgene-invests-in-ontario-developed-blood-cancer/

FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy

Largest transaction to date for Canadian-discovered preclinical asset arises from Ontario collaborators

Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia.

FACIT Makes Follow-on Investment in AI-based genomics company, DNAstack

Capital leverages Ontario’s strengths in genomics and informatics, deepens FACIT’s tech portfolio

FACIT's Compass Rose Oncology Fund is providing the follow-on investment. DNAstack also previously received capital from FACIT's early-stage Prospects Oncology Fund, illustrating FACIT's strategy to ensure promising companies grow roots and scale up in Ontario.